Changing the logic of therapeutic angiogenesis for ischemic disease

Costanza Emanueli, Paolo Madeddu

Research output: Contribution to journalArticle

Abstract

The worldwide epidemic of ischemic disease urgently requires innovative treatments. Recently, therapeutic angiogenesis has emerged as a noninvasive supply-side approach, aimed at promoting neovascularization in underperfused tissues through the local delivery of angiogenic growth factors. Successful preclinical studies paved the way for the first clinical trials, with single growth factors given as recombinant proteins or genes. However, clinical results have not matched the initial promises. Our opinion is that the logic of therapeutic angiogenesis needs profound revision. Here, we introduce the concept that pleiotropic agents can stimulate the healing of all the components of ischemic tissue. We also propose prophylactic interventions to delay vascular senescence. The optimization of therapeutic angiogenesis will open unprecedented opportunities for the care of life-threatening ischemic disease.

Original languageEnglish
Pages (from-to)207-216
Number of pages10
JournalTrends in Molecular Medicine
Volume11
Issue number5
DOIs
Publication statusPublished - May 2005

Fingerprint

Intercellular Signaling Peptides and Proteins
Angiogenesis Inducing Agents
Recombinant Proteins
Blood Vessels
Therapeutics
Clinical Trials
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Changing the logic of therapeutic angiogenesis for ischemic disease. / Emanueli, Costanza; Madeddu, Paolo.

In: Trends in Molecular Medicine, Vol. 11, No. 5, 05.2005, p. 207-216.

Research output: Contribution to journalArticle

@article{6c4dd2853fca455ca2f23cf5ca9134d8,
title = "Changing the logic of therapeutic angiogenesis for ischemic disease",
abstract = "The worldwide epidemic of ischemic disease urgently requires innovative treatments. Recently, therapeutic angiogenesis has emerged as a noninvasive supply-side approach, aimed at promoting neovascularization in underperfused tissues through the local delivery of angiogenic growth factors. Successful preclinical studies paved the way for the first clinical trials, with single growth factors given as recombinant proteins or genes. However, clinical results have not matched the initial promises. Our opinion is that the logic of therapeutic angiogenesis needs profound revision. Here, we introduce the concept that pleiotropic agents can stimulate the healing of all the components of ischemic tissue. We also propose prophylactic interventions to delay vascular senescence. The optimization of therapeutic angiogenesis will open unprecedented opportunities for the care of life-threatening ischemic disease.",
author = "Costanza Emanueli and Paolo Madeddu",
year = "2005",
month = "5",
doi = "10.1016/j.molmed.2005.03.007",
language = "English",
volume = "11",
pages = "207--216",
journal = "Trends in Molecular Medicine",
issn = "1471-4914",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Changing the logic of therapeutic angiogenesis for ischemic disease

AU - Emanueli, Costanza

AU - Madeddu, Paolo

PY - 2005/5

Y1 - 2005/5

N2 - The worldwide epidemic of ischemic disease urgently requires innovative treatments. Recently, therapeutic angiogenesis has emerged as a noninvasive supply-side approach, aimed at promoting neovascularization in underperfused tissues through the local delivery of angiogenic growth factors. Successful preclinical studies paved the way for the first clinical trials, with single growth factors given as recombinant proteins or genes. However, clinical results have not matched the initial promises. Our opinion is that the logic of therapeutic angiogenesis needs profound revision. Here, we introduce the concept that pleiotropic agents can stimulate the healing of all the components of ischemic tissue. We also propose prophylactic interventions to delay vascular senescence. The optimization of therapeutic angiogenesis will open unprecedented opportunities for the care of life-threatening ischemic disease.

AB - The worldwide epidemic of ischemic disease urgently requires innovative treatments. Recently, therapeutic angiogenesis has emerged as a noninvasive supply-side approach, aimed at promoting neovascularization in underperfused tissues through the local delivery of angiogenic growth factors. Successful preclinical studies paved the way for the first clinical trials, with single growth factors given as recombinant proteins or genes. However, clinical results have not matched the initial promises. Our opinion is that the logic of therapeutic angiogenesis needs profound revision. Here, we introduce the concept that pleiotropic agents can stimulate the healing of all the components of ischemic tissue. We also propose prophylactic interventions to delay vascular senescence. The optimization of therapeutic angiogenesis will open unprecedented opportunities for the care of life-threatening ischemic disease.

UR - http://www.scopus.com/inward/record.url?scp=18844390726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18844390726&partnerID=8YFLogxK

U2 - 10.1016/j.molmed.2005.03.007

DO - 10.1016/j.molmed.2005.03.007

M3 - Article

C2 - 15882608

AN - SCOPUS:18844390726

VL - 11

SP - 207

EP - 216

JO - Trends in Molecular Medicine

JF - Trends in Molecular Medicine

SN - 1471-4914

IS - 5

ER -